An interventional study of HAAL platform in Dementia, Devices and Artificial Intelligence, sponsored by Istituto Nazionale di Ricovero e Cura per Anziani. Recruiting at 1 site in Italy. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-03-12.
Sponsored by Istituto Nazionale di Ricovero e Cura per Anziani · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Dementia with a site in Italy — 37 open to participants now, 44 under way, 7 of them phase 3. Dementia · Italy.
Among the 92 studies in Dementia with a site in Italy, this one is the 64th largest by planned enrollment of the 66 interventional ones that give a count, is one of 12 that started in 2023, is one of 29 with no phase, reaches primary completion later than 2 of the 43 other live ones, and was the 59th registered.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
Browse Dementia studies →37 of the 92 studies in Dementia with a site in Italy are open now. Recruiting first, the newest first:
Giovanna Zamboni · Sites in Italy
Ages 40+
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Italy, Australia, Austria and 14 more countries
Ages 18+
Exciva GmbH · Sites in Italy, United States, Canada and 6 more countries
Ages 55–90
Fondazione Don Carlo Gnocchi ETS · Sites in Italy
Ages 45+
IRCCS Centro Neurolesi Bonino Pulejo · Sites in Italy
Ages 50–86
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 18 · Phase 3 25 · Phase 4 1
First in 2001; this study’s year is marked. 12 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 90 across 1,761 interventional studies indexed under Dementia.
Median enrollment 280 across the 66 interventional studies, 283 across the 26 observational. Of the 39 that completed or were terminated, 12 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 92 have an industry lead sponsor. The 10 most frequent:
Istituto Nazionale di Ricovero e Cura per Anziani is the lead sponsor of 42 studies on the registry; 21 are open to participants now.
Istituto Nazionale di Ricovero e Cura per Anziani has 4 studies filed under Dementia — fewer than ten, so there is no comparison to draw.
12 of the studies in Dementia with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07404410Giovanna ZamboniRobotic Technologies for APATHy in Dementia: a Randomised Controlled Trial (RAPHAel) | 2026-11-30 |
| NCT07625241Istituto Superiore di SanitàCST+MST Intervention on People Living With Mild-to-moderate Dementia | 2026-12 |
| NCT07287410IRCCS Centro Neurolesi Bonino PulejoDementia and Mild Cognitive Impairment: Assessment of Cognitive Functioning, Functional Autonomy, and Neuropsychiatric Symptoms. | 2026-12-20 |
| NCT05794061Istituto Auxologico ItalianoAdvances in Neuropsychological Diagnostics | 2026-12-31 |
| NCT07928453Neuromed IRCCSCardiovascular And Dementia Risk in diabeTes: the Role of Nox2- Related Oxidative Stress. | 2027-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 92 studies in Dementia with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
HAAL project aims to test several technological devices in order to improve the quality of life of older people with dementia and their informal and formal caregiver.
The HAAL study is a feasibility study. The general objectives of the HAAL project is to be assessed the stress relief at work for formal and informal caregivers, the improvement in the perceived quality of life for informal caregivers and person with dementia, the reduction in case load for the formal caregivers and the increased cost-effectiveness of the HAAL solution in comparison to the available services. The experimentation will be carried out in 3 sites: Italy, The Netherlands and Taiwan. The study consists in a alpha phase (5 older adults with dementia, 5 formal caregivers and 5 formal caregivers) and in a beta phase (10 older adults with dementia, 10 formal caregivers and 10 formal caregivers).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: HAAL platform
The HAAL platform is composed by 6 devices (lifestyle monitoring system, a smart mattress, a GPS tracking system, a social robot, an interactive game for cognitive training, and an alarm system), 1 tablet and 1 dashboard. Each user benefits of a combination of such devices, according to its own needs. The dashboard, that is used by the Formal Caregiver, receives, analyses, and show data acquired by those devices. The platform uses Artificial Intelligence (AI) algorithms - in particular machine learning (ML) is used - to analyse the collected data. The main reason for using AI in HAAL is that the platform collects data from different sensors.
Care load of caregivers
The burden of the caregiver will be assessed through the ZARIT Burden Interview (ZBI). The ZBI is a caregiver self-report measure, containing 22 items. Each item on the interview is a statement which the caregiver is asked to endorse using a 5-point scale. Response options range from 0 (Never) to 4 (Nearly Always).Total score range: 0 to 88. score range 0-21: no to mild burden; score range 21-40: mild to moderate burden; score range 41-60: moderate to severe burden score ≥ 61: severe burden.
Time frame: baseline, 1, 2, and 3 months later
Started Oct 2023 (actual). Primary completion is estimated for Apr 2024, 6 months after the start.
Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 6 months is below that.
Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituto Nazionale di Ricovero e Cura per Anziani